相关实验视频

Updated: May 5, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

免疫治疗在多种癌症中的异质性和有效性:从元分析的见解

Weidong Wu^1,2, Bin Liu³, Qing Zhang⁴

¹Henan Key Laboratory for Helicobacter Pylori and Digestive Tract Microecology, The Fifth Affiliated Hospital of Zhengzhou University; Institute of Rehabilitation Medicine, Henan Academy of Innovations in Medical Science; Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou, Henan, 450000, China.

Biological procedures online

|May 19, 2025

概括

化学抗原受体T细胞 (CAR-T) 疗法在癌症治疗中显示出显著的前景,在各种癌症中观察到高客观反应率. 需要进一步的研究来优化其在精密医学中的有效性和应用.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
生物技术是生物技术.

背景情况:

免疫疗法代表了癌症治疗的重大进步,增强了免疫系统对抗癌细胞的能力.
化学抗原受体T细胞 (CAR-T) 疗法涉及对患者的T细胞进行基因改造,以向和攻击癌细胞.
卡特-T疗法在治疗某些白血病和淋巴瘤方面表现特别有前途.

研究的目的:

进行元分析,评估免疫疗法,特别是CAR-T疗法在癌症治疗中的疗效和安全性.
分析符合条件的研究的综合数据,以确定反应率和死亡率.
根据癌症类型和患者来源进行子组分析,以确定影响治疗结果的因素.

主要方法:

通过使用PubMed,CNKI和Wanfang数据库进行了全面的文献搜索,截至2025年1月.
包括报告完全响应率 (CRR),客观响应率 (ORR) 和死亡率 (DR) 的符合条件的研究.
分析了32项涉及819-868名患者的研究的数据,并对癌症类型和起源进行了子组分析.

主要成果:

分析显示,整体客观响应率 (ORR) 为84.86%,完整响应率 (CRR) 为65.30%.
汇总的死亡率 (DR) 为23.73%.
亚组分析表明,与白血病和淋巴瘤相比,多发性髓瘤的ORR更高. 中国病例的ORR,CRR和生存率高于美国病例.

结论:

这一元分析强调了CAR-T疗法在癌症治疗中的潜力,在不同癌症类型中显示出不同的疗效.
这些发现强调了在评估治疗结果时考虑癌症类型和患者来源的重要性.
针对不同人群进行进一步的临床试验对于优化CAR-T疗法疗效和推进精准医学至关重要.

关键词:

临床结果临床结果不同的人口不同的人口.血液学的恶性瘤.响应率响应率响应率

更多相关视频

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...